Aim of this trial was to assess (1) the accuracy and precision of electrochemistry-based glucometers CONTOURLINK, CALLA, and LINUS and (2) the diabetes control using Ambulatory Glycaemic Profiles (AGP) as markers of therapeutic effectiveness. Glucometers and COBAS INTEGRA 400 Plus analyzer were used by one laboratory professional to estimate P-glucose (PG) in 112 out-patients. There were 112 sets of 12 PG estimations analyzed. In each set, means of 3 capillary PG estimations on 3 respective glucometers and on INTEGRA analyzer were calculated. The statistical program SPSS, v. 15, was applied. The mean INTEGRA PG values ranged from 2.7 to 25.3？mmol/L. There were strong correlations between mean PG on INTEGRA versus CONTOURLINK, versus CALLA, and versus LINUS; PG deviations from INTEGRA were mostly within the range ±15%. Wilcoxon Signed Rank Test revealed differences between CONTOURLINK-INTEGRA and LINUS-INTEGRA; CALLA-INTEGRA showed no difference. SD INTEGRA = 0.061？mmol/L, SD CONTOURLINK/SD CALLA/SD LINUS were 0.256/0.290/0.286？mmol/L. All patients were trained to perform defined 10-point PG profiles to adapt food, exercise, and insulin doses. The PG differences between all tested glucometers and reference values were in borderline of ISO 15197 but worthy of consideration. AGP are helpful markers of diabetes control. 1. Introduction Fasting and postprandial plasma glucose concentrations (PG) are principal diagnostic markers of diabetes mellitus. Physiological development of PG in the course of day and night is a prerequisite for the optimum physical and intellectual working capacity and prevention of diabetes complications. Therefore, the diabetes treatment is targeting on recovery of glucose homeostasis. Haemoglobin A1c brings information on long-lasting diabetes control. However, in daily life, a simple marker enabling undelayed assessment of various external factors and therapeutic outcomes is needed; ambulatory glycaemic profiles (AGP) with timing and quantity of food, exercise, and insulin dosage are known to be helpful to assess the diabetes control and the effects of various therapeutic and interfering factors [1–3]. Since the discovery of insulin by Paulescu in 1921 [4] and after its purification and introduction to human medicine by Banting, Best, Collip, and Mc Leod in 1922 [5], the needs of comfortable estimation of PG concentration are continuously growing [6, 7]. In 1974, the first glucometer (Ames) was introduced into clinical practice. To date, self-monitoring by means of various glucometer-strips systems is widely applied [8–11]. Diabetes
References
[1]
R. S. Mazze, D. Lucido, and O. Langer, “Ambulatory glucose profile: representation of verified self-monitored blood glucose data,” Diabetes Care, vol. 10, no. 1, pp. 111–117, 1987.
[2]
R. S. Mazze, E. Strock, D. Wesley et al., “Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis,” Diabetes Technology and Therapeutics, vol. 10, no. 3, pp. 149–159, 2008.
[3]
K. M. Miller, R. W. Beck, R. M. Bergenstal, et al., “T1D Exchange Clinic Network: evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1C levels in T1D Exchange Clinic Registry participants,” Diabetes Care, vol. 36, no. 7, pp. 2009–2014, 2013.
[4]
N. C. Paulesco, “Recherches sur le r？le du pancreas dans l’assimilation nutritive,” Archives Internationale De Physiologie, De Biochimie Et De Biophysique, 1921.
[5]
F. G. Banting and C. H. Best, “‘The internal secretion of the pankreas’, the journal of laboratory and clinical medicine: vol. VII St. Louis, February, 1922 No. 5,” Nutrition Reviews, vol. 45, no. 4, p. 55, 1987.
[6]
The Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, pp. 977–986, 1993.
[7]
UK Prospective Diabetes Study (UKPDS) Group, “Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34),” The Lancet, vol. 352, no. 9131, pp. 854–865, 1998.
[8]
R. M. Bergenstal, A. J. Ahmann, T. Bailey, et al., “Recommendations for standardizing glucose reporting and analysis to optimizme clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP),” Diabetes Technology & Therapeutics, vol. 15, pp. 198–211, 2013.
[9]
S. K. Garg and I. B. Hirsch, “Self-monitoring of blood glucose—an overview,” Diabetes Technology & Therapeutics, vol. 15, supplement1, pp. S-3–S-12, 2013.
[10]
“Self-monitoring of blood glucose among adults with diabetes-United States, 1997–2006,” Morbidity and Mortality Weekly Report, vol. 56, pp. 1133–1137, 2007.
[11]
I. B. Hirsch, S. A. Amiel, I. R. Blumer, et al., “Using multiple measures of glycemia to support individualized diabetes management: recommendations for clinicians, patients, and payers,” Diabetes Technology & Therapeutics, vol. 11, pp. 973–983, 2012.
[12]
R. Chlup, F. Gazárek, Z. Krikal, and B. Flasarová, “Diabetes mellitus and gravidity,” Ceská Gynekologie, vol. 41, no. 2, pp. 113–115, 1976 (Czech).
[13]
R. Chlup, R. Menzel, H. Keilacker, P. Heinke, and E. Jutzi, “Night injections of regular insulin improve diabetes control in C-peptide negative patients,” Diabetologia, vol. 40, pp. 1292–1292, 1997.
[14]
R. Chlup, H. Vaverková, and J. Bartek, “Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. I. Effects on blood glucose control,” Experimental and Clinical Endocrinology and Diabetes, vol. 105, no. 2, pp. 70–73, 1997.
[15]
R. Chlup, J. Zapletalová, P. Seckar, L. Chlupová, S. Táncosová, and M. Reznícková, “Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 Diabetes treated by means of an insulin pump,” Biomedical Papers of the Medical Faculty of Palacky University, Olomouc, Czech Republic, vol. 148, no. 1, pp. 27–32, 2004.
[16]
R. Chlup, J. Zapletalová, P. Seckar et al., “Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus,” Diabetes Technology & Therapeutics, vol. 9, no. 3, pp. 223–231, 2007.
[17]
A. Liebl, H. R. Henrichs, L. Heinemann, G. Freckmann, E. Biermann, and A. Thomas, “Continuous glucose monitoring working group of the working group diabetes technology of the German diabetes association. Continuous glucose monitoring: evidence and consensus statement for clinical use,” Journal of Diabetes Science and Technology, vol. 7, no. 2, pp. 500–519, 2013.
[18]
B. Bode, R. W. Beck, D. Xing et al., “Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes,” Diabetes Care, vol. 32, no. 11, pp. 2047–2049, 2009.
[19]
D. Rodbard, T. Bailey, L. Jovanovic, H. Zisser, R. Kaplan, and S. K. Garg, “Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring,” Diabetes Technology and Therapeutics, vol. 11, no. 11, pp. 717–723, 2009.
[20]
T. S. Bailey, H. C. Zisser, and S. K. Garg, “Reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study,” Diabetes Technology and Therapeutics, vol. 9, no. 3, pp. 203–210, 2007.
[21]
“In vitro diagnostic test systems-requirements for blood-glucose monitoring systems for self-testing in managing Diabetes mellitus,” ISO 15197, International Standards Organization, Geneva, Switzerland, 2003.
[22]
“In vitro diagnostic test systems-requirements for blood-glucose monitoring systems for self-testing in managing Diabetes mellitus,” ISO/DIS 15197, International Standards Organization, Geneva, Switzerland, 2013.
[23]
G. H. Thorpe, “Assessing the quality of publications evaluating the accuracy of blood glucose monitoring systems,” Diabetes Technology & Therapeutics, vol. 15, no. 3, pp. 253–259, 2013.
[24]
A. Baumstark, S. Pleus, C. Schmid, M. Link, C. Haug, and G. Freckmann, “Lot-to-lot variability of test strips and accuracy assessment of systems for self-monitoring of blood glucose according to ISO, 15197,” Journal of Diabetes Science and Technology, vol. 6, no. 5, pp. 1076–1086, 2012.
[25]
G. Freckmann, C. Schmid, A. Baumstark, S. Pleus, M. Link, and C. Haug, “System accuracy evaluation of 43 blood glucose monitoring systems for self-monitoring of blood glucose according to DIN EN ISO, 15197,” Journal of Diabetes Science and Technology, vol. 6, no. 5, pp. 1060–1075, 2012.
[26]
R. Chlup, J. Bartek, J. Zapletalová et al., “Vysledky mě？ení P-glukosy na glukometrech Advance a Optium v laboratorních podmínkách (Results of P-glucose estimations by means of glucometers advance and optium under laboratory conditions),” Klinicka Biochemie a Metabolismus, vol. 12, no. 3, pp. 160–170, 2004.
[27]
R. Chlup, J. Bartek, E. Malá et al., “User-oriented study on accuracy and precision of glucometer systems advance, card and optium,” Klinicka Biochemie a Metabolismus, vol. 12, no. 3, pp. 171–178, 2004.
[28]
R. Chlup, M. Payne, J. Zapletalová et al., “Results of selfmonitoring on glucometer systems advance and optium in daily routine,” Biomedical Papers of the Medical Faculty of Palacky University, Olomouc, Czech Republic, vol. 149, no. 1, pp. 127–139, 2005.
[29]
R. Chlup, B. Doubravova, K. Peterson, J. Zapletalova, and J. Bartek, “Wavesense technology glucometer Linus for routine self-monitoring and clinical practice,” Acta Diabetologica, vol. 48, no. 1, pp. 35–40, 2011.
[30]
R. Chlup, B. Doubravova, J. Zapletalova, K. Peterson, and J. Bartek, “Plasma glucose concentrations on new glucometer CALLA strongly correlate with laboratory analyser COBAS INTEGRA 400 PLUS under various clinical conditions,” Diabetes Technology & Therapeutics, vol. 13, no. 2, pp. 213–214, 2011.
[31]
R. Chlup, B. Doubravova, J. Zapletalova, K. Langova, and J. Bartek, “Glucometers, (CALLA) appear to be more convenient means for routine P-glucose monitoring in patients admitted to hospital than a laboratory analyzer (COBAS INTEGRA),” Diabetes Technology & Therapeutics, vol. 13, no. 2, pp. 214–215, 2011.
[32]
D. Rodbard, “Standardization versus customization of glucose reporting,” Diabetes Technology & Therapeutics, vol. 15, no. 5, pp. 439–443, 2013.
[33]
L. Heinemann, G. Freckmann, and T. Koschinsky, “Considerations for an institution for evaluation of diabetes technology devices to improve their quality in the European Union,” Journal of Diabetes Science and Technology, vol. 7, no. 2, pp. 542–547, 2013.
[34]
S. Garg and L. Jovanovic, “Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor,” Diabetes Care, vol. 29, no. 12, pp. 2644–2649, 2006.
[35]
D. Deiss, J. Bolinder, J.-P. Riveline et al., “Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring,” Diabetes Care, vol. 29, no. 12, pp. 2730–2732, 2006.
[36]
I. B. Hirsch, J. Abelseth, B. W. Bode et al., “Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study,” Diabetes Technology and Therapeutics, vol. 10, no. 5, pp. 377–383, 2008.
[37]
K. Peterson, J. Zapletalova, P. Kudlova et al., “Benefits of three-month continuous glucose monitoring for persons with diabetes using insulin pumps and sensors,” Biomedical Papers, vol. 153, no. 1, pp. 47–52, 2009.
[38]
J. C. Pickup, S. C. Freeman, and A. J. Sutton, “Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data,” British Medical Journal, vol. 343, no. 7815, 2011.
[39]
H. C. Yeh, T. T. Brown, N. Maruthur et al., “Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis,” Annals of Internal Medicine, vol. 157, pp. 336–347, 2012.
[40]
R. A. Vigersky, S. J. Fonda, M. Chellappa, M. S. Walker, and N. M. Ehrhardt, “Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes,” Diabetes Care, vol. 35, no. 1, pp. 32–38, 2012.
[41]
T. Battelino, I. Conget, B. Olsen et al., “The SWITCH Study Group: the use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial,” Diabetologia, vol. 55, pp. 3155–3162, 2012.
[42]
J. J. Mahoney and J. M. Ellison, “Assessing glucose monitor performance—a standardized approach,” Diabetes Technology and Therapeutics, vol. 9, no. 6, pp. 545–552, 2007.
[43]
P. Mlcák, J. Fialová, K. Trnková, and R. Chlup, “A Continuous Glucose Monitoring System (CGMS)—a promising approach for improving metabolic control in persons with type 1 Diabetes mellitus treated by insulin pumps,” Biomedical Papers of the Medical Faculty of Palacky University, Olomouc, Czech Republic, vol. 148, no. 1, pp. 33–38, 2004.
[44]
E. R. Damiano, F. H. El-Khatip, H. Zheng, D. D. Nathan, and S. J. Russell :, “A comparative effectiveness analysis of three continuous glucose monitors,” Diabetes Care, vol. 36, pp. 251–259, 2013.
[45]
I. Poljakova, E. Elsikova, R. Chlup, S. Kalabus, P. Hasala, and J. Zapletalova, “Glucose sensing module—is it time to integrate it into real-time perioperative monitoring? An observational pilot study with subcutaneous sensors,” Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic, vol. 157, no. 4, pp. 346–357, 2013.
